Skip to main content

Table 2 Baseline characteristics and outcomes of patients with IgG4-RD, grouped according to treatment

From: Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients

  GC monotherapy (n = 77) Combination therapy comprising GC and IM (n = 138) p value
Sex (male:female) 2.08:1 2.29:1 0.761
Age (years) 54 (45, 61) 54 (48, 62) 0.723
Disease duration (months) 12 (4, 24) 12 (4, 36) 0.649
IgG4-RD RI 13 (10, 18) 15 (10, 18) 0.685
Allergy history 42 (54.5%) 73 (53.7%) 1
Number of organs involved   0.369
 1 ~ 2 32 (41.6%) 46 (33.3%)  
 3 ~ 4 35 (45.5%) 66 (47.8%)  
 ≥ 5 10 (13.0%) 26 (18.8%)  
Organ involvement
 Mikulicz’s disease 51 (66.2%) 87 (63.0%) 0.659
  Dacryoadenitis 35 (45.5%) 60 (43.5%) 0.886
  Sialoadenitis 46 (59.7%) 78 (56.5%) 0.668
 Autoimmune pancreatitis 34 (44.2%) 57 (41.3%) 0.774
 Sclerosing cholangitis 22 (28.6%) 36 (26.1%) 0.749
 Retroperitoneal fibrosis 10 (13.0%) 40 (29.0%) 0.007
 Lung disease 17 (22.1%) 45 (32.6%) 0.118
 Sinusitis 25 (32.5%) 37 (26.8%) 0.433
 Lymphadenopathy 53 (68.8%) 86 (62.3%) 0.374
Laboratory tests at baseline
 Eosinophils (%) 3.3 (1.7, 6.2) 3.2 (1.4, 6.4) 0.773
 ESR (mm/h) 25 (9, 53) 25 (10, 65) 0.790
 CRP (mg/L) 2.06 (0.79, 11.24) 4.01 (1.29, 10.32) 0.297
 IgG (g/L) 18.83 (14.24, 25.54) 18.9 (15.2, 23.68) 0.747
 IgG4 (mg/L) 10,200 (3590, 18,800) 8955 (3480, 18,075) 0.554
 IgE (kU/L) 510 (178, 881) 256 (119, 728) 0.118
Initial GC dose 40 (35, 50) 40 (40,50) 0.567
Outcomes at month 6
 RI reductiona <50% 2 (2.6%) 1 (0.7%) 0.292
 Relapse 14 (18.2%) 9 (6.5%) 0.011
 Failure of GC tapering 8 (10.4%) 9 (6.5%) 0.429
 Failure of remission induction 16 (20.8%) 10 (7.2%) 0.008
  1. All the continuous non-normally distributed data were presented as median (first quartile, third quartile)
  2. IgG4-RD IgG4-related disease, RI responder index, ESR erythrocyte sedimentation rate, CRP hyper-sensitivity C-reactive protein, GC glucocorticoid, IM immunosuppressive agents
  3. aHere we considered the maximum reduction during follow up, so that re-elevation due to relapse was not taken into account